Skip to main content
Swing Capital

Krebs Biochemicals & Industries Ltd

NSE: KREBSBIO BSE: 524518Pharma

Incorporated in 1991, Krebs Biochemicals & Industries Ltd is presently engaged in manufacturing of active pharmaceutical ingredients.

₹55.7
52W: ₹38.3 — ₹114
PE 0 · Book ₹74.6 · -25% vs book
Market Cap₹120 Cr
Stock P/E—Price to Earnings
ROCE30.1%Return on Capital
ROE0%Return on Equity
Div. Yield0%Face Value ₹10

Weaknesses

  • −Company has low interest coverage ratio.
  • −The company has delivered a poor sales growth of 5.33% over past five years.

Shareholding Pattern

Promoters72.74%
FIIs0.5%
DIIs0%
Public26.77%
CategoryJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters72.74%72.74%72.74%72.74%72.74%72.74%72.74%72.74%
FIIs0.5%0.5%0.5%0.5%0.5%0.5%0.5%0.5%
DIIs0%0%0%0%0%0%0%0%
Public26.75%26.76%▲0.026.76%26.75%▼0.026.76%▲0.026.76%26.76%26.77%▲0.0

Financial Statements

MetricSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales14.8912.9811.9712.8912.8611.476.15.484.177.27
Expenses15.7915.0715.0915.0815.5816.1811.517.576.976.97
Operating Profit-0.9-2.09-3.12-2.19-2.72-4.71-5.41-2.09-2.80.3
OPM %-6.04%-16.1%-26.07%-16.99%-21.15%-41.06%-88.69%-38.14%-67.15%4.13%
Net Profit-3.57-4.98-5.85-5.17-5.76-7.74-8.27-5.32-6.14-3.13
EPS ₹-1.66-2.31-2.71-2.4-2.67-3.59-3.84-2.47-2.85-1.45

AI Insights

Revenue Trend

TTM revenue at ₹23Cr, down 46.5% YoY. OPM at -43%.

Debt Position

Borrowings at ₹219Cr. Debt-to-equity ratio: N/Ax. High leverage — monitor closely.

Capex Cycle

CWIP at ₹1Cr (1% of fixed assets). Moderate ongoing capital expenditure.

Institutional Flow

DIIs: 0% (+0.00pp change). FIIs: 0.5% (+0.00pp change). Promoters hold 72.74%.

Margin & Efficiency

ROCE declining from -4% (Sep 2014) to -30% (Mar 2025). Working capital days: -787.

Recent Announcements